Diversified Trust Co. Takes $787,000 Position in Bruker Corporation $BRKR

Diversified Trust Co. purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 16,716 shares of the medical research company’s stock, valued at approximately $787,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Bruker in the fourth quarter worth $254,000. Park Avenue Securities LLC increased its holdings in shares of Bruker by 18.3% in the 4th quarter. Park Avenue Securities LLC now owns 8,670 shares of the medical research company’s stock worth $408,000 after buying an additional 1,339 shares during the last quarter. GAMMA Investing LLC raised its position in Bruker by 77.3% during the fourth quarter. GAMMA Investing LLC now owns 4,503 shares of the medical research company’s stock valued at $212,000 after purchasing an additional 1,963 shares during the period. Allworth Financial LP lifted its stake in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in Bruker by 9,800.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 4,851 shares of the medical research company’s stock worth $158,000 after buying an additional 4,802 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BRKR shares. Jefferies Financial Group set a $50.00 price target on shares of Bruker in a report on Thursday, February 12th. Citigroup cut their price target on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a report on Wednesday, December 10th. JPMorgan Chase & Co. boosted their price objective on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, UBS Group reaffirmed a “neutral” rating and set a $49.00 price target on shares of Bruker in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $50.38.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $35.44, for a total value of $70,880.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $4,552,019.92. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 11,000 shares of company stock valued at $554,280. 27.30% of the stock is owned by company insiders.

Bruker Price Performance

Shares of BRKR stock opened at $33.72 on Friday. The company has a market cap of $5.13 billion, a P/E ratio of -224.80, a PEG ratio of 2.11 and a beta of 1.19. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The stock’s 50-day moving average is $40.06 and its 200 day moving average is $41.15. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $56.22.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The firm had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be paid a $0.05 dividend. The ex-dividend date is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker’s dividend payout ratio (DPR) is -133.33%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.